The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
A novel potential treatment for peripheral arterial disease (PAD) is described. Inhibition of SRPK1, or knockout in monocytes, induces angiogenesis by preventing splicing to antiangiogenic VEGF (VEGF-A 165 b) in patients and animal models. In PAD, monocyte splicing control is different from other cell types and SRPK1 inhibition by drug-like compounds can alter macrophage phenotype and reverse PAD in mice. A new cell-specific SRPK1-LoxP mouse is described.
